- Home
- USB vs SNY Comparison
USB vs SNY Comparison
Compare USB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USB | SNY |
|---|---|---|
| Founded | 1863 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.4B | 95.7B |
| IPO Year | 2009 | 2001 |
Fundamental Metrics
Financial Performance| Metric | USB | SNY |
|---|---|---|
| Price | $56.32 | $39.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 11 |
| Target Price | ★ $69.00 | $53.61 |
| AVG Volume (30 Days) | ★ 7.5M | 2.7M |
| Earning Date | 10-15-2026 | 10-30-2026 |
| Dividend Yield | 3.80% | ★ 4.51% |
| EPS Growth | ★ 21.90 | N/A |
| EPS | ★ 2.53 | N/A |
| Revenue | ★ $28,656,000,000.00 | N/A |
| Revenue This Year | $8.44 | $1.41 |
| Revenue Next Year | $7.15 | $6.55 |
| P/E Ratio | $22.49 | ★ $6.14 |
| Revenue Growth | ★ 4.37 | N/A |
| 52 Week Low | $45.02 | $39.07 |
| 52 Week High | $66.08 | $52.68 |
Technical Indicators
Market Signals| Indicator | USB | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 36.84 |
| Support Level | $55.40 | $39.18 |
| Resistance Level | $56.36 | $45.22 |
| Average True Range (ATR) | 0.90 | 0.61 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 17.74 | 25.13 |
Price Performance
Historical ComparisonAbout USB U.S. Bancorp
With assets of around $725 billion as of June 2026, U.S. Bancorp is one of the largest regional banks in the US with its footprint in 26 states. The bank's branch network is mostly in Midwestern and Western markets. U.S. Bancorp has a comprehensive product set, with offerings in retail and commercial banking, credit cards, mortgages, payment services, trust, wealth, and capital market services.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.